Drug Profile
Research programme: cell therapies - CIRA Biosciences
Alternative Names: Cell therapies research programme - CIRA BiosciencesLatest Information Update: 08 Jul 2013
Price :
$50
*
At a glance
- Originator CIRA Biosciences
- Class Cell therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Autoimmune disorders; Cancer; HIV infections
Most Recent Events
- 18 Mar 2013 Discontinued - Preclinical for Autoimmune disorders in USA (unspecified route)
- 18 Mar 2013 Discontinued - Preclinical for Cancer in USA (unspecified route)
- 18 Mar 2013 Discontinued - Preclinical for HIV infections in USA (unspecified route)